{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.247944","value":"0.300"},{"groupId":"OG001","spread":"0.599519","value":"0.478"},{"groupId":"OG002","spread":"0.136696","value":"0.213"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"OG000","title":"Normal Renal Function: Ixazomib"},{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"OG001","title":"Severe Renal Impairment: Ixazomib"},{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"OG002","title":"End-stage Renal Disease: Ixazomib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) evaluable population was defined as participants who received protocol-specified single dose in Part A; did not receive any excluded concomitant medications through the completion of PK sampling; and had sufficient concentration-time data to permit reliable estimation of PK parameters by non-compartmental analysis methods.","reportingStatus":"POSTED","timeFrame":"Part A, Day 1: Predose and at multiple timepoints (up to 336 hours) post-dose","title":"Unbound Cmax: Unbound Maximum Observed Plasma Concentration for Ixazomib","type":"PRIMARY","unitOfMeasure":"ng/mL"}